NEW SITE — FASTER TURNAROUND, MORE LABS. READ ON

Vendor Intelligence Report: Qingdao Sigma Chemical QSC

Published 12 Nov 2026. 37-page investigative report on who is behind Qingdao Sigma Chemical QSC: corporate records, ownership, affiliate networks, and the vendor's lab-testing record. The first 4 pages are free to read on this page.

Researched and published by Finnrick Analytics. Reports draw on corporate records, affiliate-network analysis, and Finnrick's own laboratory testing record; vendors can challenge findings through the formal objections process at finnrick.com/vendor-support/objections.

Executive summary

Across 53 Finnrick lab tests, Qingdao Sigma Chemical QSC records 33 passes and 20 failures for a 62% overall pass rate. The useful read is not the average: Tirzepatide is the most defensible tested QSC choice, Retatrutide is materially weaker, and CJC-1295 and HGH are clear avoid signals. Under stricter Finnrick grading, confidence falls further in the weak end of the catalog.

The larger buyer problem is authentication. qscpeptide.com was unreachable in the refresh, qsc-usa.com redirected into that dead end, and Telegram instructions shifted to bot-only ordering after an archived page had said website-only. QSC's own impersonation warnings and Finnrick's fraud warning for qingdaosigmachemical.com make channel verification non-optional.

Corporate records do anchor the brand to a real Qingdao company, with named shareholders and an import/export history. They do not substantiate the polished manufacturer image: public sources reviewed did not identify who controls sourcing, analytical review, QA or batch release. That is an evidence gap, not proof that competent technical staff do not exist, and it matters most because COA and vial-level traceability remain weak.

The report also maps a broad QSC-branded web network sharing analytics infrastructure, plus independent-looking rating sites that publish matching QSC data and even point to a domain QSC itself called fraudulent. Reputation risk is unusually personal here: MESO-Rx records a permanent ban for doxxing and retaliation, alongside seizure, refund and payment-recovery disputes.

Inside the full report:

  • Appendix A laboratory data with per-product pass/fail rates, methodology-divergence charts and rating trajectories for all 6 tested products
  • Chinese corporate registry, ownership and affiliate analysis for Qingdao Xige Ma Chemical and the deregistered Jiusida investment
  • Side-by-side storefront and Telegram authentication record covering the dead storefront, redirect domain, channel removal and bot migration
  • QSC-branded domain-network analysis using shared Google Analytics infrastructure and sister storefront captures
  • PeptideMeter, Medutest and VendorInvestigate comparison showing matching QSC verification data
  • COA, vial-label, Janoshik-ID, dispute, doxxing and continuity-risk evidence with source-limit notes

Risk assessment

  • CJC-1295 product-quality risk — high: 5 Finnrick tests: 1 pass / 4 fail, 27.21%; the clearest avoid signal in the tested QSC catalog.
  • HGH product-quality risk — high: 3 Finnrick tests: 0 pass / 3 fail, 33.68%; no positive Finnrick signal.
  • BPC-157 product-quality risk — high: 4 Finnrick tests: 2 pass / 2 fail, 50.72%; a coin-flip record for an injectable product.
  • Retatrutide residual quality risk — medium: 17 Finnrick tests: 11 pass / 6 fail, 71.18%; usable only with stricter batch verification or a better-testing alternative.
  • Tirzepatide residual quality risk — medium: 18 Finnrick tests: 15 pass / 3 fail, 82.42%; QSC's strongest product, but failures make batch verification material.
  • GHK-Cu limited/mixed quality risk — medium: 6 Finnrick tests: 4 pass / 2 fail, 80.65%; promising but small and split sample.
  • Storefront and channel-authentication risk — high: qscpeptide.com was NXDOMAIN/clientHold; qsc-usa.com redirects to it; Telegram says bot-only while archived site said website-only.
  • Copycat and brand-confusion risk — high: Finnrick warns not to buy from qingdaosigmachemical.com; QSC itself names multiple fraudulent domains, and verification signals remain inconsistent.
  • Astroturf verification and seller-controlled review risk — medium: PeptideMeter, Medutest and VendorInvestigate publish identical QSC data and map QSC to qingdaosigma.com; QSC's review page claims 249 reports and 100% positive.
  • Customer-retaliation and privacy risk — high: MESO-Rx records a permanent ban for doxxing and retaliation; QSC Telegram also named and linked a critic.
  • COA and batch-traceability risk — medium: Stale COA reports, no-label or sleeve-label vial reports, seller-controlled COA portal and unverified Janoshik IDs weaken vial-level verification.
  • Controlled-substance legal risk — high: QSC-branded sites list anabolic steroids and prescription-style drugs alongside peptides, including Schedule III/IV exposure in the US framework.
  • Customs-seizure and deceptive-labeling risk — high: 2018 shipment declared MONOLAURIN and Tracy interview described steroid oils labeled Honeysuckle Oil; interception risk shifts to the receiver.
  • Operational-continuity risk — high: Late-2024 raid described by QSC operator, August 2026 China shipping/restock pause, Telegram removal/bot migration and domain clientHold show fragile continuity.
  • Payment and dispute-recovery risk — medium: BTC/USDT and SWIFT flows give little chargeback leverage, and forums/Trustpilot/Reddit record unresolved loss allegations.
  • Sourcing and manufacturing-transparency risk — medium: Public claims alternate between direct manufacturer, partner-sourced supplier and licensed Indian manufacturers; product-level source and release authority are not identifiable.